Actuate Therapeutics Inc. (ACTU)
ACTU trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ACTU on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001652935 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Based on the above matters, we have concluded that there is substantial doubt regarding the Company's ability to continue as a going concern. 2." | 10-Q 2026-11-13 |
| Cash and burn | $4.4M cash; operating cash flow -$5.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 60,382,824 (2026-11-13); 23,243,328 a year earlier. | Cover page 2026-11-13 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-10-28 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-10-30 |
| Auditor | Crowe LLP, Costa Mesa, California, United States | PCAOB Form AP 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$4.9M | -$4.4M | $4.4M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$5.6M | -$5.0M | $8.1M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$4.6M | -$3.7M | $13.2M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | Not filed | -$5.4M | -$6.7M | $16.9M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | Not filed | -$5.9M | -$4.2M | $6.5M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$6.3M | -$4.6M | $3.9M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$6.4M | -$4.8M | $8.6M | $0 | Needs four quarters | 10-K 2026-03-26 |
| Q3 2024 2024-09-30 | Not filed | -$6.0M | -$9.1M | $13.5M | $0 | Needs four quarters | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2026-10-28 |
| Latest annual report FORM 10-K FOR DEC 2025 | 10-K | 2026-03-26 |
| Latest quarterly / interim FORM 10-Q SEP 2026 | 10-Q | 2026-11-13 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-30 |
| Latest proxy ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS | DEFA14A | 2026-05-06 |
Source: SEC EDGAR submissions feed, 193 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.4% |
| 1 month | -38.8% |
| 3 months | -70.8% |
| Year to date | -95.3% |
| 1 year | -95.2% |
| From 52-week high | -96.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TVRD | Tvardi Therapeutics Inc. | $1.10 | -6.78% | $14.7M |
| CTXR | Citius Pharmaceuticals Inc. | $0.5276 | -1.40% | $14.5M |
| PBM | Psyence Biomedical Ltd. Common Shares | $2.83 | -11.56% | $15.0M |
| MCRB | Seres Therapeutics Inc. | $1.41 | +0.71% | $14.4M |
| BOLT | Bolt Biotherapeutics Inc. | $5.80 | -4.61% | $15.1M |
| AKTX | Akari Therapeutics plc ADS | $6.51 | -4.26% | $15.1M |
| CNTX | Context Therapeutics Inc. | $0.1659 | -8.24% | $15.2M |
| ALLR | Allarity Therapeutics Inc. | $0.8752 | -8.24% | $13.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier